Protalix BioTherapeutics, Inc.

PLX · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances)
490
SEC Filings

Business Summary

Protalix BioTherapeutics is a commercial-stage biopharmaceutical company focused on discovery, development, production, and commercialization of therapeutics for rare diseases. It uses its proprietary ProCellEx plant cell-based protein expression system. Its approved products include Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease. Pipeline candidates include PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.

Next Earnings

Q2 FY2026 — expected 2026-08-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPLXdiscussed_in_filing Cybersecurity
topic_mentionPLXdiscussed_in_filing Trusted Computing
topic_mentionPLXdiscussed_in_filing Blockchain & Crypto
topic_mentionPLXdiscussed_in_filing Autonomous Vehicles
topic_mentionPLXdiscussed_in_filing Supply Chain
topic_mentionPLXdiscussed_in_filing Regulation
topic_mentionPLXdiscussed_in_filing Automotive
topic_mentionPLXdiscussed_in_filing Healthcare & Bio
topic_mentionPLXdiscussed_in_filing Platform & Ecosystem
topic_mentionPLXdiscussed_in_filing Networking
topic_mentionPLXdiscussed_in_filing Cybersecurity
topic_mentionPLXdiscussed_in_filing Trusted Computing
topic_mentionPLXdiscussed_in_filing Blockchain & Crypto
topic_mentionPLXdiscussed_in_filing Autonomous Vehicles
topic_mentionPLXdiscussed_in_filing Supply Chain
topic_mentionPLXdiscussed_in_filing Regulation
topic_mentionPLXdiscussed_in_filing Automotive
topic_mentionPLXdiscussed_in_filing Healthcare & Bio
topic_mentionPLXdiscussed_in_filing Platform & Ecosystem
topic_mentionPLXdiscussed_in_filing Networking

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-182025-12-310001104659-26-029858EDGAR68K words
2025-03-172024-12-310001558370-25-003039EDGAR—
2024-03-142023-12-310001558370-24-003161EDGAR—
2023-02-272022-12-310001558370-23-002102EDGAR—
2022-03-312021-12-310001558370-22-004823EDGAR—
2021-03-302020-12-310001558370-21-003681EDGAR—
2020-03-122019-12-310001104659-20-032540EDGAR—
2019-03-182018-12-310001144204-19-014464EDGAR—
2018-03-062017-12-310001144204-18-013053EDGAR—
2017-03-162016-12-310001144204-17-015083EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001104659-25-110824EDGAR22K words
2025-08-142025-06-300001558370-25-011471EDGAR—
2025-05-092025-03-310001558370-25-007063EDGAR—
2024-11-142024-09-300001558370-24-015612EDGAR—
2024-08-142024-06-300001558370-24-012134EDGAR—
2024-05-102024-03-310001558370-24-007695EDGAR—
2023-11-062023-09-300001558370-23-017664EDGAR—
2023-08-072023-06-300001558370-23-013483EDGAR—
2023-05-042023-03-310001558370-23-008132EDGAR—
2022-11-142022-09-300001558370-22-017554EDGAR—
2022-08-152022-06-300001558370-22-013560EDGAR—
2022-05-162022-03-310001558370-22-008847EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-180001104659-26-029846EDGAR4K words
2026-03-090001104659-26-024975EDGAR—
2026-02-110001104659-26-013498EDGAR—
2026-01-300001104659-26-008410EDGAR—
2026-01-050001104659-26-000393EDGAR—
2025-11-130001104659-25-110821EDGAR—
2025-11-030001104659-25-105594EDGAR—
2025-10-170001104659-25-100264EDGAR—
2025-08-220001104659-25-081924EDGAR—
2025-08-140001558370-25-011468EDGAR—

490 total filings indexed. 458 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

rare-diseases orphan-diseases gaucher-disease-treatment fabry-disease-treatment uncontrolled-gout-treatment nets-related-diseases renal-diseases plant-cell-based-protein-expression-(procellex) pegylation

Company Identity

CIK0001006281
TickerPLX
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 581a918c7b1aba6dc31892e7cda0a27bf2a301a1d8abac3ebde4fedae5c5c1e1
parent: aafd99dfe39fe7ecdea5eef9c0bd07b6d81ce34eb588d8d0520b19e354ce96f1
content hash: a61bab944cd0660d851d6cc63ddabe2a07e3b4487d37934da5bc22542737c9b7
signed: 2026-04-13T04:46:56.232Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf